Ospemifene, a novel selective estrogen receptor modulator for treating dyspareunia associated with postmenopausal vulvar and vaginal atrophy

Menopause

Volumn 20, Issue 6, 2013, Pages 623-630

  Portman, David J ^a   Bachmann, Gloria A ^b   Simon, James A ^c  

^a Columbus Center for Womens Health Research ^*  (United States)

^b ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^c GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

Author keywords

Dyspareunia; Ospemifene; Postmenopausal; Vulvar and vaginal atrophy

Indexed keywords

LUBRICATING AGENT; OSPEMIFENE; PLACEBO;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPAREUNIA; ENDOMETRIAL THICKNESS; FEMALE; HOT FLUSH; HUMAN; INCIDENCE; INTENTION TO TREAT ANALYSIS; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PH; PHASE 1 CLINICAL TRIAL; POSTMENOPAUSE; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SELF REPORT; SEXUAL BEHAVIOR; TREATMENT DURATION; URINARY TRACT INFECTION; VAGINA ATROPHY; VAGINA CANDIDIASIS; VAGINA DISCHARGE; VAGINA MYCOSIS; VAGINA PH;

ADULT; AGED; AGED, 80 AND OVER; ATROPHY; DOUBLE-BLIND METHOD; DYSPAREUNIA; FEMALE; HUMANS; MIDDLE AGED; PLACEBOS; POSTMENOPAUSE; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TAMOXIFEN; TREATMENT OUTCOME; VAGINA; VULVA;

EID: 84879172530     PISSN: 10723714     EISSN: 15300374     Source Type: Journal    
DOI: 10.1097/gme.0b013e318279ba64     Document Type: Article

References (26)

1. Mac Bride MB, Rhodes DJ, Shuster LT. Vulvovaginal atrophy. Mayo Clin Proc 2010;85:87-94.
2. Al-Baghdadi O, Ewies AA. Topical estrogen therapy in the management of postmenopausal vaginal atrophy: An up-to-date overview. Climacteric 2009;12:91-105.
3. Krychman M. Impact of vaginal atrophy on quality of life and sexuality. OBG Manag 2010;22:S14-S25.
4. The North American Menopause Society. Menopause basics. Available at: Www.menopause.org/expertadvice2.aspx. Accessed April 10, 2012.
5. US Census Bureau. Age and Sex Composition: 2010 Washington, DC: US Census Bureau, 2011. Report no. c2010BR-03.
6. Goldstein I. Recognizing and treating urogenital atrophy in postmenopausal women. J Womens Health 2010;19:425-432.
7. Santoro N, Komi J. Prevalence and impact of vaginal symptoms among postmenopausal women. J Sex Med 2009;6:2133-2142.
8. Calleja-Agius J, Brincat MP. Urogenital atrophy. Climacteric 2009;12: 279-285.
9. Nappi RE, Polatti F. The use of estrogen therapy in women's sexual functioning (CME). J Sex Med 2009;6:603-616.
10. Bachmann GA, Komi JO. Ospemifene effectively treats vulvovaginal atrophy in postmenopausal women: Results from a pivotal phase 3 study. Menopause 2010;17:480-486.
11. Winneker RC, Harris HA. Progress and prospects in treating postmenopausal vaginal atrophy. Clin Pharmacol Ther 2011;89:129-132.
12. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women-s Health Initiative randomized controlled trial. JAMA 2002;288:321-333.
13. Grady D, Ettinger B, Tosteson AN, Pressman A, Macer JL. Predictors of difficulty when discontinuing postmenopausal hormone therapy. Obstet Gynecol 2003;102:1233-1239.
14. The North American Menopause Society. The 2012 hormone therapy position statement of: The North American Menopause Society. Menopause 2012;19:257-271.
15. Pinkerton JV, Goldstein SR. Endometrial safety: A key hurdle for selective estrogen receptor modulators in development. Menopause 2010;17: 642-653.
16. Ibe C, Simon JA. Vulvovaginal atrophy: Current and future therapies (CME). J Sex Med 2010;7:1042-1050.
17. McDonnell DP. The molecular determinants of estrogen receptor pharmacology. Maturitas 2004;48(Suppl 1):S7-S12.
18. Taylor HS. Designing the ideal selective estrogen receptor modulatorV an achievable goal? Menopause 2009;16:609-615.
19. Simon JA, Lin VH, Radovich C, Bachmann GA. One-year long-term safety extension study of ospemifene for the treatment of vulvar and vaginal atrophy in postmenopausal women with a uterus. Menopause. 2012; epub ahead of print Nov 8.
20. Goldstein S, Bachmann G, Lin V, Simon J, Portman D, Phelps M. Endometrial safety profile of ospemifene 60 mg when used for long-term treatment of vulvar and vaginal atrophy for up to 1 year. Presented at: 13th World Congress for the International Menopause Society, Rome, Italy, 2011.
21. Voipio SK, Komi J, Kangas L, Halonen K, DeGregorio MW, Erkkola RU. Effects of ospemifene (FC-1271a) on uterine endometrium, vaginal maturation index, and hormonal status in healthy postmenopausal women. Maturitas 2002;43:207-214.
22. Wurz GT, Hellmann-Blumberg U, DeGregorio MW. Pharmacologic effects of ospemifene in rhesus macaques: A pilot study. Basic Clin Pharmacol Toxicol 2008;102:552-558.
23. Qu Q, Zheng H, Dahllund J, et al. Selective estrogenic effects of a novel triphenylethylene compound, FC1271a, on bone, cholesterol level, and reproductive tissues in intact and ovariectomized rats. Endocrinology 2000;141:809-820.
24. Komi J, Lankinen KS, Harkonen P, et al. Effects of ospemifene and raloxifene on hormonal status, lipids, genital tract, and tolerability in postmenopausal women. Menopause 2005;12:202-209.
25. Rutanen EM, Heikkinen J, Halonen K, Komi J, Lammintausta R, Ylikorkala O. Effects of ospemifene, a novel SERM, on hormones, genital tract, climacteric symptoms, and quality of life in postmenopausal women: A double-blind, randomized trial. Menopause 2003;10:433-439.
26. Trompeter SE, Bettencourt R, Barrett-Connor E. Sexual activity and satisfaction in healthy community-dwelling older women. Am J Med 2012;125:37-43.